Images Here
OTTAWA, ON, July 3, 2025 /PRNewswire/ -- Hard Rock Hotel & Casino Ottawa officially opened its doors today with a signature guitar smash,...
LONDON, July 3, 2025 /PRNewswire/ -- Spendstream, a leading provider of white-label rewards technology, has announced a groundbreaking partnership with Raffle House, the UK's...
TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.
Business Activity Index at 54.2%; New Orders Index at 51.3%; Employment Index at 47.2%; Supplier Deliveries Index at 50.3%
TEMPE, Ariz., July 3, 2025 /PRNewswire/...
WASHINGTON, July 3, 2025 /PRNewswire/ -- The CPSC announces today the following recalls are posted in cooperation with the firms listed below. Recalls can...
WASHINGTON, July 3, 2025 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is warning consumers to immediately stop using Bolloco Infant Bath Seats....
BOCA RATON, FL, July 03, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 17,760 Solana (“SOL”) at an average purchase price of $153.10 and valued at approximately $2.72 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 640,585 SOL and SOL equivalents, valued at approximately $98.1 million, inclusive of staking rewards.
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.
SINGAPORE, July 3, 2025 /PRNewswire/ -- Vistra, a leading provider of essential business solutions that help organisations to invest and grow efficiently and compliantly...
BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...